This is data that has been eagerly awaited. Published New England Journal of Medicine on July 21, they far exceeded the hopes of obesity specialists, and for patients, it was perhaps the beginning of a new era of care for them.
The Phase 3 Surmont-1 clinical trial evaluated the efficacy of tirzepatide, an injectable treatment developed by Eli Lilly Laboratories. Patients who received a weekly dose of 10 or 15 mg of tirzepatide lost an average of 20% of their body weight after 72 weeks. This may seem limited, but the impact on their health is very significant. “A third of these patients even achieve greater than 25% weight loss, which is unheard of with anti-obesity drugs.Dr. Lucie Favre, Senior Physician, Department of Endocrinology, Diabetology and Metabolism, Center Hospitalo-Universitaire Vaudois, Lausanne, Switzerland. Indeed, to date, only surgery…
Source: Le Figaro
